Trial Profile
A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors AbbVie
- 01 Jan 2024 Results investigating exposure-response relationships of venetoclax published in the Hematological Oncology
- 18 Nov 2021 Status changed from active, no longer recruiting to completed.
- 30 Sep 2021 Planned End Date changed from 25 Aug 2023 to 26 Nov 2021.